Natalia Buza, MD

• Akiko Iwasaki
• Alessandro Santin
• Amy Stiegler
• Austin McHenry
• Gloria Huang
• Lingeng Lu
• Lubna Pal
• Masoud Azodi
• Mitchell Clark
• Nupur Nagarkatti
• Pei Hui
• Peining Li
• Peter Schwartz
• Po-Han Chen
• Rita Abi-Raad
• Shari Damast
• Stefania Bellone
• Tobias Hartwich
• Vaagn Andikyan
• Vikram Jairam
• Yang Yang
• Yong Kong

Uterine Cervical Neoplasms; Ovarian Neoplasms; Uterine Neoplasms; Vulvar Neoplasms; Pathological Conditions, Anatomical; Gestational Trophoblastic Disease; Morphological and Microscopic Findings

• Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
• The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinomaTalia K, Banet N, Buza N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma Pathology 2022 DOI: 10.1016/j.pathol.2022.11.004.
• Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR)Hui P, Webster F, Baergen RN, Buza N, Cheung ANY, Kaur B, Ronnett BM, Shih IM, Seckl MJ, Lax SF, McCluggage WG. Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR) International Journal Of Gynecological Pathology 2022, 41: s34-s43. PMID: 36305533, DOI: 10.1097/pgp.0000000000000876.
• Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)Matias-Guiu X, Selinger CI, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Parra-Herran C, Raspollini MR, Soslow RA, Werner HMJ, Lax SF, McCluggage WG. Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR) International Journal Of Gynecological Pathology 2022, 41: s90-s118. PMID: 36305536, DOI: 10.1097/pgp.0000000000000901.
• Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)Mauricio D, Bellone S, Manavella D, Harold J, Buza N, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046) Gynecologic Oncology 2022, 166: s31-s32. DOI: 10.1016/s0090-8258(22)01265-3.
• Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.
• Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuYadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu Gynecologic Oncology 2022, 166: 351-357. PMID: 35641325, DOI: 10.1016/j.ygyno.2022.05.021.
• Gestational Trophoblastic Disease Contemporary Diagnostic ApproachBuza N. Gestational Trophoblastic Disease Contemporary Diagnostic Approach Surgical Pathology Clinics 2022, 15: 197-218. PMID: 35715158, DOI: 10.1016/j.path.2022.02.002.
• Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 CasesMcHenry A, Buza N. Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases International Journal Of Gynecological Pathology 2022, 42: 167-175. PMID: 35512214, DOI: 10.1097/pgp.0000000000000887.
• Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.
• Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesLi JY, Mutlu L, Tymon-Rosario J, Khadraoui W, Nagarkatti N, Hui P, Buza N, Lu L, Schwartz P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites Gynecologic Oncology Reports 2021, 39: 100913. PMID: 35005157, PMCID: PMC8715286, DOI: 10.1016/j.gore.2021.100913.
• A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
• Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumorsBuza N. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors Seminars In Diagnostic Pathology 2021, 39: 58-77. PMID: 34750021, DOI: 10.1053/j.semdp.2021.10.006.
• Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationshipAssem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship Human Pathology 2021, 118: 1-8. PMID: 34508766, DOI: 10.1016/j.humpath.2021.09.001.
• DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoTymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
• Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
• Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicineBuza N, Hui P. Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine Modern Pathology 2021, 34: 1658-1672. PMID: 34088998, DOI: 10.1038/s41379-021-00831-9.
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793) Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
• ImmunohistochemistryEuscher E, Buza N, Hui P. Immunohistochemistry 2021, 367-416. DOI: 10.1007/978-3-030-68608-6_15.
• Gestational Trophoblastic DiseasesBuza N, Hui P. Gestational Trophoblastic Diseases 2021, 173-191. DOI: 10.1007/978-3-030-68608-6_7.
• Intraoperative ConsultationBuza N, Euscher E. Intraoperative Consultation 2021, 317-343. DOI: 10.1007/978-3-030-68608-6_13.
• Integrated mutational landscape analysis of uterine leiomyosarcomasChoi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
• HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.Cagaanan A, Stelter B, Vu N, Rhode EN, Stewart T, Hui P, Buza N, Al-Niaimi A, Flynn C, Weisman PS, McGregor SM. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. International Journal Of Gynecological Pathology 2021, 41: 132-141. PMID: 33782344, DOI: 10.1097/pgp.0000000000000783.
• Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement studyBuza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Parra-Herran C, Rottmann D, Turner BM, Wong S, Hui P. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study Modern Pathology 2021, 34: 1194-1202. PMID: 33536574, DOI: 10.1038/s41379-021-00746-5.
• HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual MeetingBuza N. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting International Journal Of Gynecological Pathology 2020, 40: 17-23. PMID: 33290351, DOI: 10.1097/pgp.0000000000000711.
• Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohortNajjar O, Erickson B, Klein M, Dolan M, Shahi M, Grandelis A, Buza N, Tymon-Rosario J, Santin A, Ferriss J, Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort Gynecologic Oncology 2020, 159: e13. DOI: 10.1016/j.ygyno.2020.07.048.
• Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysisFader A, Roque D, Siegel E, Buza N, Hui P, Havrilesky L, Secord A, O'Malley D, Backes F, Nevadunsky N, Chambers S, Edraki B, Celano P, Bellone S, Azodi M, Ratner E, Litkouhi B, Silasi D, Schwartz P, Santin A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis Gynecologic Oncology 2020, 159: 7-8. DOI: 10.1016/j.ygyno.2020.06.014.
• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan Gynecologic Oncology 2020, 159: 177. DOI: 10.1016/j.ygyno.2020.05.265.
• Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective reviewHosier H, Haunschild C, Altwerger G, Webster E, Buza N, Tymon-Rosario J, Zeybek B, Han C, Menderes G, Huang G, Silasi D, Azodi M, Schwartz P, Santin A, Ratner E, English D. Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review Gynecologic Oncology 2020, 159: 124-125. DOI: 10.1016/j.ygyno.2020.05.150.
• Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral HeterogeneityRottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity International Journal Of Gynecological Pathology 2020, 40: 263-271. PMID: 32897955, DOI: 10.1097/pgp.0000000000000690.
• Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort studyErickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
• HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical DemandBuza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand Archives Of Pathology & Laboratory Medicine 2020, 145: 687-691. PMID: 32649220, DOI: 10.5858/arpa.2020-0207-ra.
• Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.Erickson B, Najjar O, Klein M, Shahi M, Dolan M, Cimino-Mathews A, Grandelis A, Buza N, Delaney P, Tymon-Rosario J, Santin A, Ferriss J, Stone R, Nickles Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Journal Of Clinical Oncology 2020, 38: 6084-6084. DOI: 10.1200/jco.2020.38.15_suppl.6084.
• Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell OriginSimpson S, Simoni M, Hui P, Taylor H, Buza N. Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin International Journal Of Gynecological Pathology 2020, 39: 247-253. PMID: 31033797, DOI: 10.1097/pgp.0000000000000601.
• Molecular and clinicopathologic characterization of intravenous leiomyomatosisOrdulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.
• Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation TestingChen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing International Journal Of Gynecological Pathology 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/pgp.0000000000000579.
• Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinomaPelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.
• Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patientsWong S, Hui P, Buza N. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients Modern Pathology 2020, 33: 1172-1181. PMID: 31932681, DOI: 10.1038/s41379-020-0455-x.
• Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) Gynecologic Oncology 2020, 157: 161-166. PMID: 31924334, PMCID: PMC7127981, DOI: 10.1016/j.ygyno.2019.12.034.
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapyZammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
• HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapyRottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.
• Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor EncephalitisNolan A, Buza N, Margeta M, Rabban JT. Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis The American Journal Of Surgical Pathology 2019, 43: 949-964. PMID: 31021857, DOI: 10.1097/pas.0000000000001249.
• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Buza N, Lopez S, Perrone E, Manara P, Bellone S, Zammataro L, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Journal Of Clinical Oncology 2019, 37: e17028-e17028. DOI: 10.1200/jco.2019.37.15_suppl.e17028.
• Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young womenBuza N, Baine I, Hui P. Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women Modern Pathology 2019, 32: 1271-1280. PMID: 31028360, DOI: 10.1038/s41379-019-0275-z.
• Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform molesBuza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles Modern Pathology 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.
• Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and PitfallsBuza N. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls Archives Of Pathology & Laboratory Medicine 2019, 143: 47-64. PMID: 30785337, DOI: 10.5858/arpa.2018-0289-ra.
• Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretationWu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation Modern Pathology 2018, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.
• HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous CarcinomaBlakaj A, Jairam V, Buza N, Schwartz P, Santin A, Damast S. HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s218-s219. DOI: 10.1016/j.ijrobp.2018.07.139.
• Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte J, Buza N, Hui P, Litkouhi B, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers Gynecologic Oncology 2018, 149: 70. DOI: 10.1016/j.ygyno.2018.04.159.
• Intra‐operative evaluation of prophylactic hysterectomy and salpingo‐oophorectomy specimens in hereditary gynaecological cancer syndromesWong S, Ratner E, Buza N. Intra‐operative evaluation of prophylactic hysterectomy and salpingo‐oophorectomy specimens in hereditary gynaecological cancer syndromes Histopathology 2018, 73: 109-123. PMID: 29484698, DOI: 10.1111/his.13503.
• Ancillary studies for precision diagnosis of hydatidiform molesBuza N, Hui P. Ancillary studies for precision diagnosis of hydatidiform moles Diagnostic Histopathology 2017, 23: 292-302. DOI: 10.1016/j.mpdhp.2017.05.003.
• Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMenderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Ratner E, Litkouhi B, Silasi D, Azodi M, Schwartz P, Santin A. Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression Cancer Research 2017, 77: 47-47. DOI: 10.1158/1538-7445.am2017-47.
• SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Pettinella F, Masserdotti A, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression. Journal Of Clinical Oncology 2017, 35: e14009-e14009. DOI: 10.1200/jco.2017.35.15_suppl.e14009.
• Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine CervixWong S, Hong W, Hui P, Buza N. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix International Journal Of Gynecological Pathology 2017, 36: 101-106. PMID: 27362905, DOI: 10.1097/pgp.0000000000000309.
• Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.
• Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women.Gressel G, Buza N, Pal L. Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women. Journal Of Clinical Oncology 2016, 34: e17052-e17052. DOI: 10.1200/jco.2016.34.15_suppl.e17052.
• Mismatch repair deficiency testing in clinical practiceBuza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice Expert Review Of Molecular Diagnostics 2016, 16: 591-604. PMID: 26895074, DOI: 10.1586/14737159.2016.1156533.
• Putative Precursor Lesions of Gestational Trophoblastic NeoplasiaBuza N, Hui P. Putative Precursor Lesions of Gestational Trophoblastic Neoplasia 2016, 85-102. DOI: 10.1007/978-3-319-22509-8_5.
• Diagnostic application of KRAS mutation testing in uterine microglandular proliferationsHong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.
• Intravenous Leiomyomatosis RevisitedCarr RJ, Hui P, Buza N. Intravenous Leiomyomatosis Revisited International Journal Of Gynecological Pathology 2015, 34: 169-176. PMID: 25675187, DOI: 10.1097/pgp.0000000000000127.
• Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic PathologyHui P, Buza N. Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology 2015 DOI: 10.1007/978-3-319-21807-6.
• HER2 as Biomarker for Endometrial CancerEnglish D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer 2015, 507-526. DOI: 10.1007/978-94-007-7681-4_26.
• Mitotically Active Microglandular Hyperplasia of the CervixAbi-Raad R, Alomari A, Hui P, Buza N. Mitotically Active Microglandular Hyperplasia of the Cervix International Journal Of Gynecological Pathology 2014, 33: 524-530. PMID: 25083971, DOI: 10.1097/pgp.0000000000000086.
• Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization studyBuza N, Xu F, Wu W, Carr RJ, Li P, Hui P. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study Human Pathology 2014, 45: 1885-1892. PMID: 25033729, DOI: 10.1016/j.humpath.2014.05.010.
• HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic ChallengesBuza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.
• Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad LigamentBuza N, Rutherford T, Hui P. Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament International Journal Of Gynecological Pathology 2014, 33: 58-63. PMID: 24300537, DOI: 10.1097/pgp.0b013e31827cd386.
• HER2 as Biomarker for Endometrial CancerEnglish D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer 2014, 1-16. DOI: 10.1007/978-94-007-7744-6_26-1.
• Ancillary Techniques to Refine Diagnosis of GTDBuza N, Hui P. Ancillary Techniques to Refine Diagnosis of GTD Current Obstetrics And Gynecology Reports 2013, 3: 65-75. DOI: 10.1007/s13669-013-0072-5.
• Presentation and management of borderline ovarian tumors: Should mucinous tumors be managed differently?Black J, Yoo N, Rutherford T, Tavassoli F, Ratner E, Buza N, Azodi M, Schwartz P. Presentation and management of borderline ovarian tumors: Should mucinous tumors be managed differently? Gynecologic Oncology 2013, 130: e148-e149. DOI: 10.1016/j.ygyno.2013.04.420.
• Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelRoque D, Buza N, Glasgow M, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel Gynecologic Oncology 2013, 130: e124-e125. DOI: 10.1016/j.ygyno.2013.04.358.
• Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D, Santin A, Azodi M, Schwartz P, Hui P, Rutherford T. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564] Gynecologic Oncology 2012, 125: 770. DOI: 10.1016/j.ygyno.2012.02.026.
• New diagnostic modalities in the histopathological diagnosis of hydatidiform molesBuza N, Hui P. New diagnostic modalities in the histopathological diagnosis of hydatidiform moles Diagnostic Histopathology 2012, 18: 201-209. DOI: 10.1016/j.mpdhp.2012.02.004.
• Partial Hydatidiform MoleBuza N. Partial Hydatidiform Mole 2011, 77-90. DOI: 10.1007/978-1-61779-394-3_5.
• Urinary hCG Screening in the Gynecologic Oncology PopulationRichter C, Buza N, Hui P, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. Urinary hCG Screening in the Gynecologic Oncology Population Journal Of Gynecologic Surgery 2011, 27: 143-146. DOI: 10.1089/gyn.2010.0048.
• Gestational trophoblastic disease: histopathological diagnosis in the molecular eraBuza N, Hui P. Gestational trophoblastic disease: histopathological diagnosis in the molecular era Diagnostic Histopathology 2010, 16: 526-537. DOI: 10.1016/j.mpdhp.2010.08.002.
• Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinomaSantin A, Bellone S, El-Sahwi K, Buza N, Tavassoli F, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S. Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma Journal Of Clinical Oncology 2009, 27: e16502-e16502. DOI: 10.1200/jco.2009.27.15_suppl.e16502.